Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kazia TherapeuticsKZIA -2.60%33 PB Ratio is 4.41 as of Sep. 09, 2026, which is 305% above its 10-year median of 1.09. GuruFocus rates KZIA with a GF Score™ of 33/100. The stock has 5 warning signs investors should review. Among 1,215 Biotechnology companies, Kazia Therapeutics ranks worse than 64.53% on this metric.
Kazia Therapeutics Ltd stock PB Ratio (=4.41) is close to 3-year high of 4.41.
The historical rank and industry rank for Kazia Therapeutics's PB Ratio or its related term are showing as below:
KZIA'
s PB Ratio Range Over the Past 10 Years
Min: 0.09 Med: 1.09 Max: 5.4
Current: 4.41
During the past 13 years, Kazia Therapeutics's highest PB Ratio was 5.40. The lowest was 0.09. And the median was 1.09.
KZIA's PB Ratio is ranked worse than 64.53% of 1215
companies
in the Biotechnology industry
Industry Median: 2.99
vs KZIA: 4.41
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Kazia Therapeutics was 67.40% per year. The lowest was -48.10% per year. And the median was -16.75% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Kazia Therapeutics PB Ratio Related Terms
Kazia Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Kazia Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Kazia Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kazia Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kazia Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Kazia Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Kazia Therapeutics (KZIA) has a PB Ratio of 4.41 as of Sep. 09, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Kazia Therapeutics and its competitors. This is 305% above median its historical median of 1.09. Over the past decade, Kazia Therapeutics' PB Ratio has ranged from 0.09 to 5.40. According to the industry distribution chart, Kazia Therapeutics ranks #784 out of 1215 companies in the Biotechnology industry, placing it in the top 64.5%.
Is Kazia Therapeutics' PB Ratio too high?
Kazia Therapeutics' current PB Ratio of 4.41 is 305% above median its 10-year median of 1.09. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 5.40. The Biotechnology industry median PB Ratio is 2.99. Kazia Therapeutics' value of 4.41 is 47.5% above this industry median. Based on the distribution chart, Kazia Therapeutics ranks #784 out of 1215 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Kazia Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Kazia Therapeutics' PB Ratio compare to OKUR and TNYA?
According to the Biotechnology industry distribution chart, Kazia Therapeutics ranks #784 out of 1215 companies for PB Ratio. This places Kazia Therapeutics in the lower half of its industry. The industry median PB Ratio is 2.99. Kazia Therapeutics' value of 4.41 is 47.5% above this benchmark. Historically, Kazia Therapeutics' own PB Ratio has ranged from 0.09 to 5.40 over the past decade. While the company's 10-year median is 1.09 vs. the industry median of 2.99, Kazia Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.99, based on 1,215 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kazia Therapeutics's current PB Ratio of 4.41 is 47.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Kazia Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kazia Therapeutics's current PB Ratio is 4.41, which is 305% above median its own 10-year median of 1.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kazia Therapeutics stock overvalued right now?
Kazia Therapeutics (KZIA) has a current PB Ratio of 4.41. The current PB Ratio is 4.41, which is 305% above median its 10-year median of 1.09 and 47.5% above the Biotechnology industry median of 2.99. Kazia Therapeutics' overall GF Score™ is 33/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Kazia Therapeutics (KZIA), the current PB Ratio is 4.41 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
33GF Score
Get the complete analysis for KZIA
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KZIA has been successfully added to your 
